Evan A. Thackaberry, Ph.D., D.A.B.T. has been a Toxicologist at Genentech since 2010. In this capacity, he serves as the safety assessment therapeutic area leader for ophthalmology, and as project toxicologist and non-clinical lead for several ophthalmology and oncology program. Dr. Thackaberry is currently the Vice President of the Society of Toxicology Ocular Toxicology Specialty Section, and has been a diplomate of the American Board of Toxicology since 2006. He is an expert on non-clinical and clinical formulation safety assessment, and has published extensively in the area. Prior to joining Genentech, Dr. Thackaberry received his B.A. in Biochemistry from the University of Vermont, and a Ph.D. in Molecular and Environmental Toxicology from the University of Wisconsin-Madison, where his research focused on the Aryl Hydrocarbon Receptor in cardiovascular development. After graduation, he studied the effects of prenatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin on cardiovascular development at the University of New Mexico, and collaborated with the Lovelace Respiratory Research Institute to study the effects on diesel exhaust on cardiovascular development. Prior to joining Genentech, Dr. Thackaberry served as a regulatory and investigative toxicologist at the Schering-Plough Research Institute, developing early and late stage products across numerous therapeutic areas, and serving as an expert on formulation safety assessment.